This study is looking at whether empagliflozin, a medication, can help heart transplant recipients. After a heart transplant, people can be at higher risk for kidney and heart problems. Empagliflozin has shown benefits for kidney and heart health in other groups of patients. This study will compare empagliflozin to a placebo (an inactive pill) over 12 months to see if it can help improve kidney health, specifically by looking at a marker in your urine called UACR (Urinary albumin-to-creatinine ratio). Researchers will also monitor for any side effects. You may be able to join if you are 18 or older, had a heart transplant at least 3 months ago, and meet other health requirements. The study plans to enroll 200 participants.

Study design

This is an interventional study that will randomly assign 200 participants to receive either empagliflozin or a placebo.

What's involved

You would take empagliflozin 10 mg or a placebo daily for 12 months. Baseline testing will be completed before starting the medication.

Compensation

Not stated in the trial record.

Follow-up

Your kidney health and any side effects will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.